clinical comprehensive evaluation study of the effect of Anjunning on heroin dependence

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-14005041

Enrollment

Unknown

Registered

2014-08-01

Start date

2009-03-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

heroin dependence

Interventions

anjunning group:anjunning

anjunning with Buprenorphine group:anjunning with Buprenorphine

Placebo:Placebo

Eligibility

Sex/Gender

All

Age

18 Years to 55 Years

Inclusion criteria

Inclusion criteria: The inclusion criteria included patients age from 18 to 55 years with a diagnosis of heroin dependence; a heroin-positive urine analysis detected by thin-layer chromatography (TLC); the last drug used from 8 to 36 hours; written informed consent.

Exclusion criteria

Exclusion criteria: The exclusion criteria included serious opiate withdrawal symptoms including disturbance of consciousness or serious vehement or severe dehydration or the attempt of suicide; current psychiatric illnesses or dementia pregnancy or breast feeding; the serious infectious diseases and the serious disease of heart lung kidney liver central nervous system, hematopoietic cancer or an inability to understand the consent process; the allergy history of the study drug.

Countries

China

Contacts

Public ContactJing LI

joana028@163.com+86 18980601715

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026